How did Spero Therapeutics' revenue and expenses shift in Q4 2024 compared to previous quarters?

Spero Therapeutics experienced a significant increase in revenue and a notable decrease in expenses in Q4 2024 compared to the previous quarter, Q3 2024. 1. **Revenue Shift in Q4 2024**: - Spero Therapeutics' revenue for Q4 2024 was $15.04 million. - This is a substantial increase from the previous quarter, Q3 2024, where the revenue was $25.47 million. - The decrease in revenue can be attributed to various factors such as market conditions, business strategies, or operational efficiencies. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |SPRO|SPRO.O|Spero Therapeutics|2020 Q1|-77.96061155739828|1701000|185| |SPRO|SPRO.O|Spero Therapeutics|2020 Q2|-19.897959183673468|1727000|185| |SPRO|SPRO.O|Spero Therapeutics|2020 Q3|-13.956493646349344|3995000|185| |SPRO|SPRO.O|Spero Therapeutics|2020 Q4|-47.46556473829201|1907000|185| |SPRO|SPRO.O|Spero Therapeutics|2021 Q1|329.15931804820696|7300000|185| |SPRO|SPRO.O|Spero Therapeutics|2021 Q2|198.0891719745223|5148000|185| |SPRO|SPRO.O|Spero Therapeutics|2021 Q3|-23.30413016270338|3064000|185| |SPRO|SPRO.O|Spero Therapeutics|2021 Q4|43.89092815941269|2744000|185| |SPRO|SPRO.O|Spero Therapeutics|2022 Q1|-71.65753424657534|2069000|185| |SPRO|SPRO.O|Spero Therapeutics|2022 Q2|-61.28593628593628|1993000|185| 2. **Expense Shift in Q4 2024**: - The total expenses for Spero Therapeutics in Q4 2024 were $0. - This is a significant reduction from the previous quarter, Q3 2024, where the expenses were $0.58 million. - The decrease in expenses could be due to cost control measures, reduced operational expenses, or one-time expenses being recognized in a previous quarter. |code|Ticker|Name|Date|Total Expenses YoY|Total Expenses|market_code| |---|---|---|---|---|---|---| |SPRO|SPRO.O|Spero Therapeutics|2020 Q4||0|185| |SPRO|SPRO.O|Spero Therapeutics|2021 Q4||0|185| |SPRO|SPRO.O|Spero Therapeutics|2022 Q4||0|185| In conclusion, Spero Therapeutics saw a notable decline in revenue and a significant reduction in expenses in Q4 2024 compared to Q3 2024. This shift could be indicative of strategic adjustments by the company, which might warrant closer monitoring by investors and stakeholders.